Multiparametric MR diffusion‐weighted imaging for monitoring the ultra‐early treatment effect of sorafenib in human hepatocellular carcinoma xenografts

X Chen, Z Ma, Y Huang, L He, C Liang… - Journal of Magnetic …, 2017 - Wiley Online Library
Purpose To investigate the value of multiparametric magnetic resonance imaging (MRI)
diffusion‐weighted imaging (DWI) for monitoring the ultra‐early (within 24 hours) treatment …

Diffusion-weighted MRI of advanced hepatocellular carcinoma during sorafenib treatment: initial results

C Schraml, NF Schwenzer… - American Journal of …, 2009 - Am Roentgen Ray Soc
OBJECTIVE. The objective of our study was to evaluate signal changes of advanced
hepatocellular carcinoma in diffusion-weighted MRI in the early-response monitoring of oral …

Evaluation of antiangiogenic and antiproliferative effects of sorafenib by sequential histology and intravoxel incoherent motion diffusion‐weighted imaging in an …

S Yang, J Lin, F Lu, Z Han, C Fu, P Lv… - Journal of Magnetic …, 2017 - Wiley Online Library
Purpose To investigate the effectiveness of intravoxel incoherent motion (IVIM) in the
assessment of the therapeutic efficacy of sorafenib in an orthotopic hepatocellular …

Assessment of early therapeutic response to sorafenib in renal cell carcinoma xenografts by dynamic contrast-enhanced and diffusion-weighted MR imaging

TY Jeon, CK Kim, JH Kim, GH Im… - The British Journal of …, 2015 - academic.oup.com
Objective: To investigate the feasibility of dynamic contrast-enhanced MRI (DCE-MRI) and
diffusion-weighted MRI (DWI) in monitoring early therapeutic response to sorafenib in renal …

Comparison of dynamic contrast-enhanced magnetic resonance imaging and contrast-enhanced ultrasound for evaluation of the effects of sorafenib in a rat model of …

NM Muñoz, AA Minhaj, KL Maldonado… - Magnetic Resonance …, 2019 - Elsevier
Objectives To compare the accuracy of contrast-enhanced ultrasound (CEUS) and Dynamic
contrast-enhanced (DCE) magnetic resonance imaging (MRI) for the assessment of …

Multimodal imaging of tumor response to sorafenib combined with radiation therapy: comparison between diffusion‐weighted MRI, choline spectroscopy and 18F …

O Karroum, L Mignion, J Kengen… - Contrast media & …, 2013 - Wiley Online Library
The purpose of this study was to determine the value of different imaging modalities, that is,
magnetic resonance imaging/spectroscopy (MRI/MRS) and positron emission tomography …

Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and …

CY Hsu, YC Shen, CW Yu, C Hsu, FC Hu, CH Hsu… - Journal of …, 2011 - Elsevier
BACKGROUND & AIMS: Sorafenib plus metronomic tegafur/uracil therapy can induce tumor
stabilization in advanced hepatocellular carcinoma (HCC) patients. This study evaluated the …

[HTML][HTML] Magnetic resonance imaging following treatment of advanced hepatocellular carcinoma with sorafenib

JI Choi, DK Imagawa, P Bhosale… - Clinical and …, 2014 - ncbi.nlm.nih.gov
Hepatocellular carcinomas are highly vascular tumors, showing progressive
hypervascularity by the process of neoangiogenesis. Tumor angiogenesis is critical for …

Perfusion magnetic resonance as a biomarker for sorafenib-treated advanced hepatocellular carcinoma: a pilot study

M Campos, I Candelária, N Papanikolaou… - GE-Portuguese Journal …, 2019 - karger.com
Background: Sorafenib is the currently recommended therapy in patients with advanced
hepatocellular carcinoma (HCC). Among the several biomarkers available for the evaluation …

[HTML][HTML] Magnetic resonance imaging biomarkers in hepatocellular carcinoma: association with response and circulating biomarkers after sunitinib therapy

DV Sahani, T Jiang, K Hayano, DG Duda… - Journal of hematology & …, 2013 - Springer
Background To investigate the hypothesis that MRI derived diffusion-weighted imaging
(DWI) and perfusion (MRP) parameters are sensitive image biomarkers for monitoring early …